Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers

HaemophiliaEarly View LETTER TO THE EDITOR Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers Chatphatai Moonla, Chatphatai Moonla orcid.org/0000-0001-6257-0867 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorChantana Polprasert, Chantana Polprasert orcid.org/0000-0001-6949-4449 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorSan Krittikarux, San Krittikarux Department of Medicine, Sakaeo Crown Prince Hospital, Sakaeo, ThailandSearch for more papers by this authorNuanrat Cheerasiri, Nuanrat Cheerasiri orcid.org/0000-0002-7470-5340 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorBenjaporn Akkawat, Benjaporn Akkawat Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorPonlapat Rojnuckarin, Corresponding Author Ponlapat Rojnuckarin [email protected] orcid.org/0000-0001-7912-1996 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Correspondence Ponlapat Rojnuckarin, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Rama IV Road, Pathumwan, Bangkok 10330, Thailand. Email: [email protected]Search for more papers by this authorNoppacharn Uaprasert, Noppacharn Uaprasert orcid.org/0000-0003-4562-9139 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this author Chatphatai Moonla, Chatphatai Moonla orcid.org/0000-0001-6257-0867 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorChantana Polprasert, Chantana Polprasert orcid.org/0000-0001-6949-4449 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorSan Krittikarux, San Krittikarux Department of Medicine, Sakaeo Crown Prince Hospital, Sakaeo, ThailandSearch for more papers by this authorNuanrat Cheerasiri, Nuanrat Cheerasiri orcid.org/0000-0002-7470-5340 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorBenjaporn Akkawat, Benjaporn Akkawat Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this authorPonlapat Rojnuckarin, Corresponding Author Ponlapat Rojnuckarin [email protected] orcid.org/0000-0001-7912-1996 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Correspondence Ponlapat Rojnuckarin, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Rama IV Road, Pathumwan, Bangkok 10330, Thailand. Email: [email protected]Search for more papers by this authorNoppacharn Uaprasert, Noppacharn Uaprasert orcid.org/0000-0003-4562-9139 Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandSearch for more papers by this author First published: 04 September 2023 https://doi.org/10.1111/hae.14850 Ponlapat Rojnuckarin and Noppacharn Uaprasert are co-last authors. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015; 125(7): 1091-1097. 2Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020; 105(7): 1791-1801. 3Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012; 120(1): 47-55. 4Cai H, Cao X, Wang S, Zhao Y, Li J, Zhu TN. Rituximab and bortezomib for patients with newly diagnosed acquired heamophilia: single arm, single center, prospective phase 2 study. Blood. 2022; 140(Suppl 1): 2715-2716. 5Markmann C, Bhoj VG. On the road to eliminating long-lived plasma cells—“are we there yet?” Immunol Rev. 2021; 303(1): 154-167. 6Moonla C, Uaprasert N, Watanaboonyongcharoen P, et al. Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages. Haemophilia. 2021; 27(1): e155-e159. 7Dobbelstein C, Moschovakis GL, Tiede A. Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study. Ann Hematol. 2020; 99(9): 2105-2112. 8Frerichs KA, Bosman PWC, van Velzen JF, et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica. 2020; 105(6): e302-e306. 9Casneuf T, Xu XS, Adams HC, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017; 1(23): 2105-2114. 10Liu W, Liu J, Xue F, Yang R, Zhang L. Anti-CD38 antibody for refractory acquired hemophilia A. J Thromb Haemost. 2023; 21(6): 1515-1518. 11Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021; 137(3): 410-419. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation